1619-62-1

Basic information

• Product Name: DIETHYL DIMETHYLMALONATE
• Synonyms: 2,2-dimethyl-malonicaciddiethylester;Diethyl 2,2-dimethylmalonate;Malonic acid, dimethyl-, diethyl ester;DIETHYL DIMETHYLMALONATE;Dimethylmalonic Acid Diethyl Ester;2,2-Dimethylpropanedioic acid diethyl ester;Diethyl dimethylmalonate,97%;Propanedioic acid, 2,2-diMethyl-, 1,3-diethyl ester
• CAS NO: 1619-62-1
• Molecular Formula: C₉H₁₆O₄
• Molecular Weight: 188.22
• EINECS: 216-582-6
• Product Categories: Pharmaceutical Intermediates;C8 to C9;Carbonyl Compounds;Esters
• Mol File: 1619-62-1.mol
• Article Data: 30

Chemical Properties

• Melting Point: -30.4°C
• Boiling Point: 192 °C(lit.)
• Flash Point: 160 °F
• Appearance: Clear colorless/Liquid
• Density: 0.991 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.387mmHg at 25°C
• Refractive Index: n20/D 1.412(lit.)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: DIETHYL DIMETHYLMALONATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIETHYL DIMETHYLMALONATE(1619-62-1)
• EPA Substance Registry System: DIETHYL DIMETHYLMALONATE(1619-62-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-52/53
• Safety Statements: 24/25-61
• WGK Germany: 3
• Hazardous Substances Data: 1619-62-1(Hazardous Substances Data)

Usage

Chemical Properties

CLEAR COLOURLESS LIQUID

General Description

Diethyl dimethylmalonate forms adducts with α,α,α′,α′-tetraaryl-1,3-dioxolane-4,5-dimethanol based titanium catalysts.

InChI:InChI=1/C9H16O4/c1-5-12-7(10)9(3,4)8(11)13-6-2/h5-6H2,1-4H3

Upstream product

• 5659-97-2 dimethyl-malonyl bromide 
• 105-53-3 diethyl malonate 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 5471-77-2 3-ethoxy-2,2-dimethyl-3-oxopropanoic acid 
• 74-83-9 methyl bromide 
• 609-08-5 Diethyl methylmalonate 
• 105-56-6 ethyl 2-cyanoacetate 
• 75511-41-0 2,2-bis(ethoxycarbonyl)-1-bromopropane 
• 429-42-5 tetrabutylammonium tetrafluoroborate 
• 442672-21-1 tert-butyl 4-ethoxy-3-(ethoxycarbonyl)-3-methyl-4-oxobutaneperoxoate 
• 71-43-2 benzene 

Downstream Products

• 96-22-0 pentan-3-one 
• 79-31-2 isobutyric Acid 
• 594-88-7 3-hydroxy-2,2,3-trimethylbutanoic acid 
• 1888-57-9 2,5-dimethylhexan-3-one 
• 108-83-8 diisobutyl ketone 
• 589-55-9 heptan-4-ol 
• 2198-72-3 4-propylheptan-4-ol 
• 7379-12-6 n-propyl isopropyl ketone 
• 123-19-3 4-heptanone 
• 97-62-1 Ethyl isobutyrate 
• 19424-43-2 2,3,3,4-tetramethylpentane-2,4-diol 
• 62817-86-1 3-hydroxy-2,2,3-trimethyl-butyric acid ethyl ester 
• 67-64-1 acetone 
• 57186-07-9 4,4-dimethyl-1-phenylpyrazolidine-3,5-dione 

Relevant articles and documents

REACTION MECHANISMS FOR ELECTROCHEMICAL CARBON-SKELETON REARRANGEMENT AS CATALYZED BY HYDROPHOBIC VITAMIN B12 IN NONAQUEOUS MEDIA

Reaction mechanisms for the controlled-potential electrolysis of 2,2-bis(ethoxycarbonyl)-1-bromopropane at -1.0, -1.5, and -2.0 V vs.SCE as catalyzed by a hydrophobic vitamin B12 were clarified.

A Convenient Synthesis of Diethyl Dialkyl- and Dibenzylmalonates via Extractive Alkylation

-

Methylcorrinoids methylate radicals - Their second biological mode of action?

-

Characterization of a Simple Vitamin B12 Model Complex and Its Catalysis in Electrochemical Carbon-Skeleton Rearrangement

The electrochemical carbon-skeleton rearrangement reaction of 2,2-bis(ethoxycarbonyl)-1-bromopropane was catalyzed by the cobalt complex of 2,10-diethyl-3,9-dipropyl-1,4,8,11-tetraazaundeca-1,3,8,10-tetraene-1,10-diol, which was characterized by ESR spectroscopy and cyclic voltammetry.

Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups

Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.